Articles published by Appili Therapeutics Inc.

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

December 15, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

November 13, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

October 25, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Presents at the 10th International Tularemia Conference

September 27, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

September 25, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

August 11, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics – Press Release Correction

June 23, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

June 23, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

May 24, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 18, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF

Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

April 03, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

February 14, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

January 17, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

January 13, 2023

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

November 14, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

November 10, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

September 22, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

August 12, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

August 02, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results

June 29, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

April 27, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

April 13, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

February 28, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022

February 14, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

February 08, 2022

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors

November 19, 2021

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer

November 12, 2021

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™

November 12, 2021

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction

September 29, 2021

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19

September 23, 2021

From Appili Therapeutics Inc.

Via Business Wire

Tickers APLIF TSX:APLI

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.